Literature DB >> 9196114

Observer variation and relationship of computed tomography to severity of beryllium disease.

E M Daniloff1, D A Lynch, B B Bartelson, J D Newell, S M Bernstein, L S Newman.   

Abstract

Although high resolution computed tomography (HRCT) is commonly used to assess interstitial lung disease (ILD), relatively little is known about interrater reliability and construct validity of HRCT-reported nodules, ground-glass opacity, or other typical findings. We determined the interobserver and intraobserver variability of HRCT findings and correlated HRCT abnormalities with physiologic measures in 57 patients with chronic beryllium disease (CBD). Reliability of HRCT scan measurements were assessed using weighted kappa (K(W)) and intraclass correlation coefficients. We correlated HRCT with spirometry, body plethysmographic lung volumes, diffusing capacity for carbon monoxide (DL(CO)), maximal exercise testing with measurement of arterial blood gases, and bronchoalveolar lavage (BAL). Interobserver agreement for three of the HRCT abnormalities found in CBD was moderate: the K(W) for nodules, septal lines, and ground-glass attenuation were 0.53, 0.44, and 0.53, respectively. Agreement was poor for bronchial wall thickening (K(W) = 0.15). HRCT scores correlated significantly with DL(CO), gas exchange at rest and at maximal exercise, and lung volume. This study demonstrates that HRCT has good interrater reliability and correlates with indices of the severity of granulomatous lung diseases such as CBD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9196114     DOI: 10.1164/ajrccm.155.6.9196114

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  3 in total

1.  A combined pulmonary-radiology workshop for visual evaluation of COPD: study design, chest CT findings and concordance with quantitative evaluation.

Authors:  R Graham Barr; Eugene A Berkowitz; Francesca Bigazzi; Frederick Bode; Jessica Bon; Russell P Bowler; Caroline Chiles; James D Crapo; Gerard J Criner; Jeffrey L Curtis; Chandra Dass; Asger Dirksen; Mark T Dransfield; Goutham Edula; Leif Erikkson; Adam Friedlander; Maya Galperin-Aizenberg; Warren B Gefter; David S Gierada; Philippe A Grenier; Jonathan Goldin; MeiLan K Han; Nicola A Hanania; Nadia N Hansel; Francine L Jacobson; Hans-Ulrich Kauczor; Vuokko L Kinnula; David A Lipson; David A Lynch; William MacNee; Barry J Make; A James Mamary; Howard Mann; Nathaniel Marchetti; Mario Mascalchi; Geoffrey McLennan; James R Murphy; David Naidich; Hrudaya Nath; John D Newell; Massimo Pistolesi; Elizabeth A Regan; John J Reilly; Robert Sandhaus; Joyce D Schroeder; Frank Sciurba; Saher Shaker; Amir Sharafkhaneh; Edwin K Silverman; Robert M Steiner; Charlton Strange; Nicola Sverzellati; Joseph H Tashjian; Edwin J R van Beek; Lacey Washington; George R Washko; Gloria Westney; Susan A Wood; Prescott G Woodruff
Journal:  COPD       Date:  2012-03-19       Impact factor: 2.409

2.  Infliximab therapy modulates an antigen-specific immune response in chronic beryllium disease.

Authors:  Lisa A Maier; Briana Q Barkes; Margaret Mroz; Milton D Rossman; Juliana Barnard; May Gillespie; Allison Martin; Douglas G Mack; Lori Silveira; Richard T Sawyer; Lee S Newman; Andrew P Fontenot
Journal:  Respir Med       Date:  2012-09-11       Impact factor: 3.415

3.  Sarcoidosis: assessment of disease severity using HRCT.

Authors:  Marjolein Drent; Jolanda De Vries; Merinke Lenters; Rob J S Lamers; Snjezana Rothkranz-Kos; Emiel F M Wouters; Marja P van Dieijen-Visser; Johny A Verschakelen
Journal:  Eur Radiol       Date:  2003-06-17       Impact factor: 5.315

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.